MCF Advisors
CRSP icon

MCF Advisors’s CRISPR Therapeutics CRSP Stock Holding History

MCF Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-2,187
Closed -$119K – 611
2026
Q2 		$119K Hold
2,187
– – ﹤0.01% 511
2026
Q1 		$104K Hold
2,187
– – ﹤0.01% 493
2025
Q4 		$115K Buy
2,187
+150
+7% +$8.98K 0.01% 384
2025
Q3 		$132K Hold
2,037
– – 0.01% 302
2025
Q2 		$99.1K Hold
2,037
– – 0.01% 310
2025
Q1 		$69.3K Hold
2,037
– – 0.01% 357
2024
Q4 		$80.2K Buy
+2,037
New +$96.2K 0.01% 342
2024
Q2 		– Sell
-20
Closed -$1.36K – 1036
2024
Q1 		$1.36K Buy
+20
New +$1.43K ﹤0.01% 851

Other funds holding CRSP

Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Concurrent Investment Advisors
Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return
Slow Capital
Slow Capital Greenbrae, California $890M AUM 40.96% 1-Year Est. Return
State of Michigan Retirement System
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 32.98% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return
NTV Asset Management
NTV Asset Management Charleston, West Virginia $1.08B AUM 23.94% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

MCF Advisors's CRSP Position: Q3 2026 in Review

MCF Advisors sold out of CRISPR Therapeutics (CRSP) in Q3 2026, closing a stake of 2,187 shares — an estimated $119K sold.

MCF Advisors first reported a position in CRSP in Q1 2024 and held it in 8 quarters. The position peaked at $132K in Q3 2025. 189 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.

  • MCF Advisors reported no remaining CRISPR Therapeutics position as of Q3 2026 after selling out during the quarter.
  • MCF Advisors sold 2,187 CRISPR Therapeutics shares in Q3 2026, an estimated $119K.
  • MCF Advisors first reported a position in CRISPR Therapeutics in Q1 2024 and held it in 8 quarters.
  • MCF Advisors's CRISPR Therapeutics position peaked at $132K in Q3 2025.
  • 189 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.

Based on MCF Advisors's 13F filing for Q3 2026, filed 28 Oct 2026.